MINI REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1569897
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 45 articles
TROP2: as a promising target in lung cancer
Provisionally accepted
Xing xing Li1,2*
Jia li Chen1,2- 1The First People's Hospital of Linping, Hangzhou, China
- 2Department of Medical Oncology, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung cancer (LC) is a significant global health concern, underscoring the need for ongoing research into novel therapeutic modalities. Trophoblast cell surface antigen-2 (TROP2) is overexpressed in tumor tissues and minimally expressed in normal tissues, making it a promising target for cancer treatment. A TROP2-targeted antibody-drug conjugate (ADC) has been approved by the Food and Drug Administration (FDA).This review aims to provide a comprehensive overview of the characteristics of TROP2 and its role in cancer development. It is imperative to acknowledge the significant advancements made in the realm of LC therapy through the development of ADCs that specifically target the TROP-2 antigen. The potential of the TROP-2 ADC in the treatment of LC is a subject of considerable promise, suggesting a promising future in the therapeutic management of this condition.
Keywords: Tacstd2, Trop2, Antibody-drug conjugate, lung cancer, Lung Adenocarcinoma
Received: 05 Mar 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xing xing Li, The First People's Hospital of Linping, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.